This is a routine insider sale via option exercise, small relative to market cap. No material signal; monitor for any pattern of larger insider sales in future filings.
REGN drugs
REGN drug pipeline →- ● Otarmeni 3/10 Approved (accelerated approval) · BLA filing 2026
- ▲ Cemdisiran 6/10 Filed/PDUFA (Phase 3 NIMBLE complete; NDA under FDA Priority Review)
- ▲ Dupixent 4/10 Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion)
- ● Evkeeza 4/10 Approved
- ● EYLEA HD 4/10 Approved
- 12 more · All REGN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $902.90entry
- T+1 · 11d ago +0.16%α −0.15% · $904.35
- T+5 · 5d ago +5.35%α +2.06% · $951.19
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Jason Pitofsky, an officer of Regeneron Pharmaceuticals, filed a Form 144 notice of intent to sell 3,883 shares of common stock via cashless exercise of stock options granted in 2020, 2021, and 2022. The shares are valued at approximately $3.79 million based on the filing date, representing a small fraction of the company's $99.4 billion market cap.
Key Facts
- Jason Pitofsky, an officer of Regeneron, filed a Form 144 on November 4, 2026
- The filing covers 3,883 shares of common stock
- Shares are to be sold via cashless exercise of stock options granted on 12/09/2020 (905 shares), 12/08/2021 (1,478 shares), and 12/16/2022 (1,500 shares)
- The approximate market value of the shares is $3,789,808
- The sale is scheduled for November 4, 2026
- The shares represent a very small portion of the company's $99.4B market cap (approximately 0.004%)
Financial Impact
Approximately $3.79 million in shares to be sold, representing about 0.004% of market cap
Risk Factors
- Form 144 is an intent to sell, not a completed transaction; the sale may not occur
- Insider selling via option exercise is common and not necessarily a negative signal
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001969223-26-001125 |
| Document: 0001969223-26-001125-index.html | 0001969223-26-001125 |
| Document: 0001969223-26-001125.txt | 0001969223-26-001125 |
Track record
53 reports on REGN
11 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 21 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
- Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
- Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Viewing Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers